An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients
Introduction
The incidence of brain tumours is low compared to other common cancer sites such as breast and lung. Primary brain tumours account for only 2–3% of all cancers in adults.1 However, despite its low incidence, brain cancer is a disease characterised by severe symptoms and poor prognosis. Currently, efforts at developing new therapeutic strategies in brain cancer are focused on prolonging survival. However, these treatments may increase neurotoxicity2 and thereby negatively affect health-related quality of life (HRQOL). Special concerns exist with regard to cognitive dysfunction and personality changes.3 Consequently, clinical benefits of any new treatment should be weighed against treatment side-effects that adversely influence patients’ HRQOL.
In assessing the HRQOL of brain cancer patients it is important to use well-validated instruments. Today, the most widely used brain cancer-specific HRQOL questionnaires are the brain subscale of the Functional Assessment of Cancer Therapy (FACT-Br)4 and the EORTC brain cancer-specific Quality of Life Questionnaire (QLQ-BN20).5
The QLQ-BN20 has previously been tested in English-speaking samples, and has been demonstrated to have adequate psychometric properties.5 The purpose of the study reported here was to examine the validity and reliability of the QLQ-BN20 in an international setting, in multiple languages.
Section snippets
Patients
In this study we used data derived from two phase III EORTC/NCIC cancer clinical trials (EORTC Protocol 269516 and 268917). These studies were merged in order to create a large dataset (N = 941) in an international and cross-cultural setting.
Trial 26951 included 368 patients with newly diagnosed highly anaplastic oligodendroglioma (i.e. anaplastic oligodendroglioma or anaplastic oligo-astrocytoma), who were randomly assigned to either six cycles of adjuvant Procarbazine-CCNU-Vincristine (PCV)
Patient characteristics
Of the total sample of 941 brain cancer patients from the two clinical trials, 891 (94.7%) completed at least one HRQOL assessment and were included in the analysis. These patients were enroled by 119 institutions from 15 countries. Baseline socio-demographic and clinical characteristics for these 891 patients (see Table 1) were very similar to those of the total sample (data not shown).
Questionnaire completion rates
Based on the total patient sample (N = 941) the baseline questionnaire completion rate was 83%. HRQOL
Discussion
The objective of this study was to generate detailed data on the psychometric properties of the EORTC QLQ-BN20 HRQOL questionnaire module when used in a diverse sample of patients with primary brain tumours participating in large scale, international clinical trials. Such large scale, international field-testing of the questionnaire is important, given that it, along with the EORTC core HRQOL questionnaire (the QLQ-C30), is one of the most widely used measures for assessing HRQOL in brain
Conflict of interest statement
Dr. Stupp has served on advisory boards for Bristol-Myers Squibb, Merck KGaA, Roche and Schering-Plough.
Dr. Mirimanoff has received speaking engagements including travel and accommodation from Schering-Plough.
Dr. Van den Bent has been a consultant for Schering-Plough, has acted as a member for their speakersbureau and has received research grants from Schering-Plough.
Acknowledgements
This publication was supported by Grants no. 2U10 CA11488-37 from the National Cancer Institute (Bethesda, Maryland, USA) and by a donation from the KWF Kankerbestrijding from the Netherlands through the EORTC Charitable Trust. This analysis is funded by the EORTC Quality of Life Group. Its content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Cancer Institute.
References (19)
- et al.
Health-related quality of life in patients with glioblastoma: a randomized controlled trial
Lancet Oncol
(2005) - et al.
Mini-mental state: a practical method for grading the cognitive state for the clinician
J Psychiat Res
(1975) - et al.
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
Lancet Oncol
(2006) - US News & World Report: Brain Tumor Channel. Cleveland Clinic [cited 2007 July]. Available from: URL:...
- et al.
Health-related quality of life and symptom research in glioblastoma multiforme patients
Expert Rev Parmacoeconomics Outcomes Res
(2005) - et al.
Impact of brain tumour treatment on quality of life
J Neurol
(2002) - et al.
The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors
Cancer
(1995) - et al.
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires
Qual Life Res
(1996) - et al.
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial
J Clin Oncol
(2006)
Cited by (275)
Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study
2024, Journal of Clinical NeuroscienceUntoward global effects of current guideline formulation of stereotactic radiotherapy for symptomatic brain metastases by international medical societies
2023, Lancet Regional Health - Americas